Clinical And Therapeutic Studies Of Human Filariasis

人类丝虫病的临床和治疗研究

• 批准号: 6985593
• 负责人: THOMAS B NUTMAN
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6985593
• 关键词: Pacific Islander; Rickettsiales; South American; anthelmintics; benzimidazoles; biopsy; cell migration; clinical trials; communicable disease diagnosis; diagnosis design /evaluation; disease /disorder etiology; enzyme linked immunosorbent assay; eosinophil; filariasis; human subject; human therapy evaluation; immune response; immunocytochemistry; inflammation; microorganism disease chemotherapy; onchocerciasis; patient oriented research; polymerase chain reaction; strongyloidiasis; therapy design /development

To understand better the pathogenesis of filarial infections (onchocerciasis, loiaisis, lymphatic filarasis) clinical assessments of patients with these and other related non-filarial (strongyloides, malaria) infections have been studied in detail. Moreover, the post-treatment inflammatory responses and the underlying mechanisms in their induction have been detailed. In particular, the control of eosinophil induction and cell trafficking to sites of post-treatment inflammation has been studied. The importance of the Wolbachia endosymbiont both as a therapeutic target and as a inducer of inflammation has been detailed as well. In FY 2003, we demonstrated the relative paucity of adverse reactions seen following ivermectin/albendazole treatment of lymphatic filariasis in Mali and have shown that co-infection with Mansonella perstans does little to alter the post-treatment reactions.

为了更好地了解丝虫感染（盘尾丝虫病、洛伊斯病、淋巴丝虫病）的发病机制，对这些和其他相关非丝虫（类圆线虫病、疟疾）感染患者的临床评估进行了详细研究。此外，治疗后的炎症反应及其诱导的潜在机制已被详细说明。特别是，已经研究了嗜酸性粒细胞诱导和细胞运输到治疗后炎症部位的控制。Wolbachia内共生体作为治疗靶点和作为炎症诱导剂的重要性也已详细说明。 在2003财政年度，我们证明了伊维菌素/阿苯达唑治疗马里淋巴丝虫病后的不良反应相对较少，并表明与持久性曼森氏菌合并感染对治疗后反应的改变很小。